A prospective ICU follow-up study converted midazolam and lorazepam to a common exposure measure, illustrating why calculated equivalence must remain separate from measured drug concentrations.
The study followed cognition after intensive care
The researchers assessed adult ICU survivors at planned intervals over a year using telephone versions of cognitive screening instruments. They modeled change over time and adjusted selected analyses for clinical factors, including benzodiazepine exposure. Scores were standardized within instrument rather than treated as directly interchangeable raw totals.
The paper reported improvement during follow-up, particularly at earlier intervals. That recovery analysis did not randomly assign benzodiazepine use or test a benzodiazepine tapering intervention. It should not be presented as proof that changing one sedative caused cognitive recovery.
The exposure measure required assumptions
The investigators converted benzodiazepine amounts to lorazepam equivalents using route-specific factors. Intravenous and oral midazolam had different factors, and lorazepam was the reference. They also described a sensitivity analysis using an alternative intravenous midazolam conversion.
These choices acknowledge that equal milligram amounts do not necessarily represent equal exposure or effect across drugs and routes. They also make the resulting exposure variable a calculated research construct. A lorazepam-equivalent total is not a laboratory lorazepam concentration, and it does not establish identical sedation in two individuals.
Follow-up and baseline information limited inference
The authors acknowledged incomplete follow-up, missing covariates, and possible underrepresentation of people too impaired to complete telephone testing. They also lacked formal pre-ICU cognitive assessments. An improving follow-up score therefore cannot establish return to that person’s premorbid baseline.
For a forensic medication reconstruction, the relevant lesson is to preserve the original drug, route, dose, and timing even when a common unit is used for analysis. Conversion factors and sensitivity checks should be disclosed, and uncertainty should not disappear when exposure is reduced to one number. This paper demonstrates transparent modeling choices rather than validating a universal equivalence rule for clinical or legal use.
Source paper
Original analysis of the supplied journal article, identified as PMC12908703.
Leave a Reply